508. OUTCOME OF NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN EAST ASIA VERSUS WESTERN EUROPE
Ben M. Eyck(Erasmus MC Cancer Institute), Jan van Lanschot(Erasmus MC Cancer Institute), Yin‐Kai Chao(Chang Gung University), Zhigang Li(National Institutes of Health), Sjoerd M. Lagarde(University of Amsterdam), Simon Law(Inserm), M Hulshof, Yang Yang(Zhengzhou University), Jue Liu(Peking University), Xing Gao(Xuzhou Medical College), Ko Lam(Queen Mary Hospital), Yhi Wong(University of Hong Kong), Berend Van Der Wilk(Erasmus MC), Bas P. L. Wijnhoven(Erasmus MC Cancer Institute)
Cited by 0
Related Papers
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
|Nature Genetics|2014|1.1k
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
|Nature Genetics|2009|788
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|788
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
|Nature Genetics|2011|775